<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506385</url>
  </required_header>
  <id_info>
    <org_study_id>294/CE</org_study_id>
    <nct_id>NCT04506385</nct_id>
  </id_info>
  <brief_title>Metabolomic Effects of Probiotics Administration</brief_title>
  <acronym>MAPPINg</acronym>
  <official_title>EFFECTS OF PROBIOTICS ADMINISTRATION ON HUMAN METABOLIC PHENOTYPE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probiotical S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Probiotical S.p.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The establishment of the beneficial interactions between the host and its&#xD;
      microbiota is essential for the development and correct functioning of the organism, since&#xD;
      microflora alterations can lead to many chronic degenerative diseases. In this context,&#xD;
      probiotics are used to improve balanced microbial communities and therefore exert substantial&#xD;
      health-promoting effects to the host.&#xD;
&#xD;
      Objective: The aim of the present study is to monitor the molecular outcomes, obtained by gut&#xD;
      microflora modulation through probiotic treatment, on human urine and serum metabolic&#xD;
      profiles, with a 1H-Nuclear Magnetic Resonance -based metabolomic approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: In a first phase twenty-two healthy subjects are enrolled in the study and&#xD;
      administered with Lactobacillus delbrueckii subs. delbrueckii and/or a mix of 5 biotypes of&#xD;
      Bifidobacterium longum for 8 weeks. In the second phase subjects are enrolled in the study&#xD;
      and administered with Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus&#xD;
      fermentum and Bifidobacterium longum at two different concentration. During the course of the&#xD;
      study all the probiotic types were administered both singularly and in combination. From each&#xD;
      subject urine and serum samples are collected before and during the supplementation and are&#xD;
      analysed by nuclear magnetic resonance spectroscopy and statistical analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metabolomic profile</measure>
    <time_frame>20 days</time_frame>
    <description>To monitor the molecular outcomes, obtained by gut microflora modulation through probiotic treatment, on human urine and serum metabolic profiles, with a 1H-Nuclear Magnetic Resonance-based metabolomic approach</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Metabolomic Profile</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L. delbrueckii LDD01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bifidobacterium longum DLBL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: low dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: high dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - healthy subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous surgery on the intestinal tract;&#xD;
&#xD;
          -  a probiotic / prebiotic and antibiotic treatments within 3 and 1 months, respectively,&#xD;
             before the beginning of the study;&#xD;
&#xD;
          -  subjects have changed drastically their diet or lifestyle during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria Maggiore della carit√† di Novara</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

